Evidence map›Paper›PMID 41355362›Full record

ReviewBrain and behavior2025

Therapeutic and Diagnostic Roles of MSC-Derived Exosomes in Alzheimer's Disease.

Vinay Shankar Patil, Bhavin Parekh, Amit Sharma, Husni Farah, Renuka Jyothi-S, Swati Mishra, Anima Nanda, Shaker Al-Hasnaawei, Manoj Kumar-Mishra

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vinay Shankar PatilArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA.
Bhavin ParekhArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA.
Amit SharmaArnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA.
Husni FarahFaculty of Allied Medical Sciences, Hourani Center For Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Renuka Jyothi-SDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Swati MishraDepartment of Pharmacology, IMS and SUM Hospital, Siksha 'O' Anusandhan, Bhubaneswar, Odisha, India.
Anima NandaDepartment of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Shaker Al-HasnaaweiCollege of Pharmacy, the Islamic University, Najaf, Iraq.
Manoj Kumar-MishraCollege of Business and Economics, Salale University, Fitche, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlzheimer's disease (AD), the leading cause of dementia, is characterized by amyloid-β accumulation, tau hyperphosphorylation, neuroinflammation, and synaptic failure, with no curative therapies available. This review aims to explore innovative therapeutic and diagnostic strategies, focusing on mesenchymal stem cell-derived exosomes (MSC-exos) as potential disease-modifying agents.

methodThe review synthesizes current evidence on the regenerative, immunomodulatory, and neuroprotective properties of mesenchymal stem cells (MSCs) and their exosomes. It examines how MSC-exos, as nanosized extracellular vesicles carrying proteins, lipids, and nucleic acids, interact with the central nervous system to modulate disease pathways.

findingsMSC-exos can cross the blood-brain barrier (BBB), deliver neurotrophic factors, modulate microglial activity, enhance amyloid clearance, and support neuronal survival and synaptic plasticity. They also hold promise as biomarkers by reflecting central nervous system pathology in peripheral biofluids. Early clinical trials using MSCs from bone marrow, adipose tissue, and umbilical cord show safety and feasibility, with exosome-based approaches offering scalable, cell-free alternatives.

conclusionMSC-derived exosomes present a promising avenue for both therapeutic intervention and early diagnosis in AD, offering neuroprotective, anti-inflammatory, and pro-regenerative effects. However, further progress requires addressing challenges such as exosome isolation standardization, cargo characterization, and regulatory considerations to enable their translation into clinical practice.

Indexed as

Alzheimer DiseaseExosomesMesenchymal Stem CellsAnimalsBlood-Brain BarrierEarly DiagnosisHumansImmunomodulationMesenchymal Stem Cell TransplantationRegenerationAlzheimer's diseasebiomarkersexosomesmesenchymal stem cellsneuroregeneration

Identifiers

PMID41355362
PMCPMC12683074

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.